LU91372I2 - Retapamulin optionnellement sous forme d'un sel pharmaceutiquement acceptable (altargo) - Google Patents

Retapamulin optionnellement sous forme d'un sel pharmaceutiquement acceptable (altargo)

Info

Publication number: LU91372I2
Authority: LU; Luxembourg
Prior art keywords: altargo; retapamulin; optionally; pharmaceutically acceptable; acceptable salt
Prior art date: 1997-10-29

Application number

LU91372C

Other languages

English (en)

Other versions

LU91372I9 (fr

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-10-29

Filing date

2007-10-24

Publication date

2007-12-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26312507&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91372(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-10-29 Priority claimed from GBGB9722817.5A external-priority patent/GB9722817D0/en

1998-06-25 Priority claimed from GBGB9813689.8A external-priority patent/GB9813689D0/en

2007-10-24 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2007-12-24 Publication of LU91372I2 publication Critical patent/LU91372I2/fr

2019-01-02 Publication of LU91372I9 publication Critical patent/LU91372I9/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/32—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C271/36—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems

LU91372C 1997-10-29 2007-10-24 Retapamulin optionnellement sous forme d'un sel pharmaceutiquement acceptable (altargo) LU91372I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9722817.5A GB9722817D0 (en)	1997-10-29	1997-10-29	Novel compounds
GBGB9813689.8A GB9813689D0 (en)	1998-06-25	1998-06-25	Novel compounds
PCT/GB1998/003211 WO1999021855A1 (fr)	1997-10-29	1998-10-27	Derives de pleuromutiline utilises comme agents antimicrobiens

Publications (2)

Publication Number	Publication Date
LU91372I2 true LU91372I2 (fr)	2007-12-24
LU91372I9 LU91372I9 (fr)	2019-01-02

Family

ID=26312507

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU91372C LU91372I2 (fr)	1997-10-29	2007-10-24	Retapamulin optionnellement sous forme d'un sel pharmaceutiquement acceptable (altargo)

Country Status (36)

Country	Link
US (3)	US6281226B1 (fr)
EP (3)	EP1930330B1 (fr)
JP (2)	JP4227729B2 (fr)
KR (1)	KR100538721B1 (fr)
CN (1)	CN1205211C (fr)
AR (1)	AR015987A1 (fr)
AT (2)	ATE525373T1 (fr)
AU (1)	AU742167C (fr)
BR (1)	BR9814747B1 (fr)
CA (1)	CA2307551C (fr)
CO (1)	CO5021129A1 (fr)
CY (2)	CY2007028I1 (fr)
CZ (1)	CZ298543B6 (fr)
DE (2)	DE69826704T3 (fr)
DK (2)	DK1930330T3 (fr)
DZ (1)	DZ2634A1 (fr)
EG (1)	EG24177A (fr)
ES (2)	ES2229538T7 (fr)
FR (1)	FR07C0057I2 (fr)
HK (1)	HK1031376A1 (fr)
HU (2)	HU229792B1 (fr)
IL (2)	IL135811A0 (fr)
LU (1)	LU91372I2 (fr)
MY (1)	MY130665A (fr)
NL (1)	NL300304I2 (fr)
NO (3)	NO327392B1 (fr)
NZ (1)	NZ504203A (fr)
PE (1)	PE123299A1 (fr)
PL (2)	PL191927B1 (fr)
PT (2)	PT1930330E (fr)
SI (2)	SI1930330T1 (fr)
TR (1)	TR200001203T2 (fr)
TW (1)	TWI232861B (fr)
UY (1)	UY25225A1 (fr)
WO (1)	WO1999021855A1 (fr)
ZA (1)	ZA989767B (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UY25225A1 (es) *	1997-10-29	2000-12-29	Smithkline Beecham Plc	Derivados de pleuromutilina utiles como agentes antimicrobianos
WO2000027790A1 (fr) *	1998-11-11	2000-05-18	Smithkline Beecham P.L.C.	Composes a base de mutiline
GB9912657D0 (en) *	1999-06-01	1999-07-28	Smithkline Beecham Plc	Novel compounds
GB9918037D0 (en) *	1999-07-30	1999-09-29	Biochemie Gmbh	Organic compounds
GB9919839D0 (en) *	1999-08-20	1999-10-27	Smithkline Beecham Plc	Novel compounds
ES2328109T3 (es) *	2000-04-04	2009-11-10	Smithkline Beecham Plc	Derivados de carbamato de 2-hihrosimutilina para uso antibacteriano.
GB0017073D0 (en) *	2000-07-11	2000-08-30	Univ London	Microorganism
GB0017031D0 (en)	2000-07-11	2000-08-30	Biochemie Gmbh	Antimicrobials
PE20020676A1 (es) *	2000-09-13	2002-08-27	Biochemie Gmbh	Compuestos de mutilina como antibacterianos
GB0024811D0 (en) *	2000-10-10	2000-11-22	Smithkline Beecham Plc	Novel compounds
GB0027705D0 (en)	2000-11-11	2000-12-27	S P A	Novel compounds
FR2835186B1 (fr) *	2002-01-28	2006-10-20	Aventis Pharma Sa	Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
GB0207495D0 (en) *	2002-03-28	2002-05-08	Biochemie Gmbh	Organic compounds
CN100355729C (zh) *	2002-07-24	2007-12-19	桑多斯股份公司	截短侧耳素
GB0218578D0 (en)	2002-08-09	2002-09-18	Glaxo Group Ltd	Novel method
GB0308114D0 (en) *	2003-04-08	2003-05-14	Glaxo Group Ltd	Novel compounds
ATE450535T1 (de) *	2003-09-03	2009-12-15	Glaxo Group Ltd	Neues verfahren zur herstellung von pleuromutilinderivaten
JP2007537261A (ja) *	2004-05-13	2007-12-20	グラクソ　グループ　リミテッド	ムスカリン性アセチルコリン受容体アンタゴニスト
GB0504314D0 (en) *	2005-03-02	2005-04-06	Glaxo Group Ltd	Novel polymorph
WO2006104667A2 (fr) *	2005-03-10	2006-10-05	Smithkline Beecham Corporation	Nouveau procede
WO2007000004A1 (fr) *	2005-06-27	2007-01-04	Nabriva Therapeutics Forschungs Gmbh	Derives de la pleuromutiline contenant un groupe hydroxyamino- ou acyloxyaminocycloalkyle
GB0513058D0 (en) *	2005-06-27	2005-08-03	Sandoz Ag	Organic compounds
WO2007037518A1 (fr) *	2005-09-29	2007-04-05	Dainippon Sumitomo Pharma Co., Ltd.	Derive de mutiline et composition pharmaceutique la contenant
WO2007079173A2 (fr) *	2005-12-30	2007-07-12	Emergent Biosolutions Inc.	Nouveaux dérivés de 2-hétéroaryloxyphénol au titre d'agents antibactériens
KR20090107567A (ko)	2007-02-09	2009-10-13	아스텔라스세이야쿠 가부시키가이샤	아자 가교환 화합물
WO2008117796A1 (fr) *	2007-03-28	2008-10-02	Dainippon Sumitomo Pharma Co., Ltd.	Nouveaux dérivés de mutiline
EP2149571A4 (fr)	2007-05-24	2010-09-01	Kyorin Seiyaku Kk	Dérivé de la mutiline ayant une structure d'acide carboxylique à noyau aromatique hétérocyclique en substituant à la position 14
US20090076071A1 (en) *	2007-09-13	2009-03-19	Protia, Llc	Deuterium-enriched retapamulin
TW200936582A (en) *	2007-11-26	2009-09-01	Teva Pharma	Amorphous retapamulin and processes for preparation thereof
WO2009075776A1 (fr) *	2007-12-05	2009-06-18	Teva Pharmaceutical Industries Ltd.	Procédé pour préparer de la rétapamuline et ses intermédiaires
US8278313B2 (en)	2008-03-11	2012-10-02	Abbott Laboratories	Macrocyclic spiro pyrimidine derivatives
US8436005B2 (en)	2008-04-03	2013-05-07	Abbott Laboratories	Macrocyclic pyrimidine derivatives
WO2010056855A1 (fr) *	2008-11-13	2010-05-20	Teva Pharmaceutical Industries Ltd.	Préparation de rétapamuline par l'intermédiaire de son précurseur pleuromutiline-thiol
WO2010100720A1 (fr) *	2009-03-03	2010-09-10	独立行政法人放射線医学総合研究所	Réactif de mesure de l'activité cholinestérase
US8710046B2 (en)	2009-07-14	2014-04-29	Albany Molecular Research, Inc.	5-HT3 receptor modulators, methods of making, and use thereof
CN102344397B (zh) *	2011-08-23	2013-09-04	浙江升华拜克生物股份有限公司	一种伐奈莫林盐酸盐的提纯方法
CN103626693B (zh) *	2012-08-28	2016-09-14	中国科学院上海药物研究所	一类截短侧耳素衍生物、其药物组合物及其合成方法与用途
CN103709093B (zh) *	2012-09-28	2016-06-08	山东亨利医药科技有限责任公司	含有并环的截短侧耳素类抗生素
EP3689219B1 (fr)	2014-07-21	2023-08-30	EndoChoice, Inc.	Systèmes d'endoscope à foyers multiples et à caméra multiples
WO2017151492A1 (fr)	2016-03-02	2017-09-08	Anacor Pharmaceuticals, Inc.	Petites molécules contenant du bore
US10874679B2 (en)	2016-03-02	2020-12-29	Bill & Melinda Gates Foundation	Boron-containing small molecules
WO2017151489A1 (fr)	2016-03-02	2017-09-08	Anacor Pharmaceuticals, Inc.	Petites molécules contenant du bore
CN106496085B (zh) *	2016-09-21	2018-01-26	盐城市舜宝化工有限公司	合成盐酸沃尼妙林的中间体化合物以及盐酸沃尼妙林的制备方法
TWI762573B (zh)	2017-02-10	2022-05-01	奧地利商納畢瓦治療有限責任公司	截短側耳素之純化
CN111574395B (zh) *	2020-06-18	2021-07-02	华南农业大学	一种具有酰胺侧链的截短侧耳素衍生物及制备与应用
AT523646B1 (de)	2020-07-21	2021-10-15	Gerd Dr Ascher	Pharmazeutische Verbindungen, ihre Anwendung alleine oder in Kombination, zur Prophylaxe und lokalen Initial-Therapie bei bakteriellen und viralen Infektionen, insbesondere Coronaviren
US11155514B1 (en) *	2020-12-19	2021-10-26	Shaanxi University Of Science And Technology	Pleuromulin acitretin ester with antibacterial activity and a method of preparing the same
US11332430B1 (en) *	2021-01-25	2022-05-17	Xi'an Taikomed Pharmaceutical Technology Co., Ltd.	Pleuromulin lauric acid ester with antibacterial activity and a method of preparing the same
CN112919463B (zh) *	2021-04-09	2021-10-26	南京理工大学	一种利用泰妙菌素废盐制备的活性炭及其制备方法
CN113121355B (zh) *	2021-04-13	2023-05-09	西安康诺化工有限公司	一种截短侧耳素大黄酸酯及其制备方法和应用
CN114736194A (zh) *	2022-03-29	2022-07-12	中牧实业股份有限公司	一种具有抗病原微生物活性的含吡啶季铵盐侧链的截短侧耳素衍生物及其制备方法与应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4060542A (en)	1969-07-25	1977-11-29	Biochemie Gesellschaft M.B.H.	14-Desoxy-14 thiocyanato-acetoxy-mutilin
CH575375A5 (fr)	1972-05-25	1976-05-14	Sandoz Ag
US4208326A (en)	1971-10-05	1980-06-17	Sandoz Ltd.	Pleuromutilin esters
US4032530A (en)	1971-10-05	1977-06-28	Sandoz Ltd.	Certain pleuromutilins
BE789629A (fr) *	1971-10-05	1973-04-03	Sandoz Sa	Nouveaux derives de la pleuromutiline, leur preparation et leurapplication en therapeutique
US3919290A (en)	1972-10-03	1975-11-11	Sandoz Ltd	Substituted 14-desoxy-mutilins
CH593912A5 (en)	1972-07-07	1977-12-30	Sandoz Ag	Pleuromutilin derivs. - prepd. by acylating derivs. contg. a (4)-hydroxyalkyl-(1)-piperazinyl gp.
DE2404046C3 (de)	1974-01-29	1984-07-26	Henkel KGaA, 4000 Düsseldorf	Verwendung von Carboxyl- bzw. Carboxylat- und Hydroxylgruppen aufweisenden Polymeren als Hautfeuchthaltemittel
US3987194A (en)	1975-05-12	1976-10-19	E. R. Squibb & Sons, Inc.	Use of pleuromutilin derivatives for the treatment of swine dysentery
CH619450A5 (fr)	1976-01-15	1980-09-30	Sandoz Ag
US4130709A (en)	1977-12-08	1978-12-19	Eli Lilly And Company	Pleuromutilin glycoside derivatives
GB2025930B (en) *	1978-06-01	1983-02-09	Sandoz Ltd	Process for the production of pleuromutilin derivatives
DE2966635D1 (en) *	1979-01-12	1984-03-08	Sandoz Ag	New pleuromutilin derivatives, their production and pharmaceutical compositions containing them
ZA80175B (en) *	1979-01-12	1981-08-26	Sandoz Ltd	New pleuromutilin derivatives, their production and use
FR2502951B1 (fr)	1981-04-06	1985-12-06	Sandoz Sa	Compositions pharmaceutiques topiques sous forme d'une micro-emulsion
EP0153277B1 (fr) *	1984-02-17	1987-08-26	Sandoz Ag	Dérivés de pleuromutiline, leur procédé de préparation et leur application
DE3405632A1 (de) *	1984-02-17	1985-08-22	Sandoz-Patent-GmbH, 7850 Lörrach	Neue pleuromutilinderivate, verfahren zu ihrer herstellung und ihre verwendung
AT400674B (de)	1991-07-24	1996-02-26	Biochemie Gmbh	Pharmazeutische pleuromutilin-zubereitung
GB9201751D0 (en)	1992-01-28	1992-03-11	Smithkline Beecham Plc	Compounds
AT397654B (de)	1992-05-04	1994-06-27	Biochemie Gmbh	Neue pleuromutilinderivate, ihre verwendung und verfahren zu ihrer herstellung
WO1996020173A1 (fr)	1994-12-23	1996-07-04	Dr. Karl Thomae Gmbh	Derives de piperazine, medicaments contenant ces composes, leur utilisation et leur procede de preparation
BR9612426A (pt)	1996-01-03	1999-07-13	Smithkline Beecham Plc	Derivados carbomoilóxi e sua aplicação como antibacterianos
HUP0001741A3 (en)	1996-08-02	2000-11-28	Smithkline Beecham Plc	Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use, process for preparing them, pharmaceuticals contg. them and their use
AU724070B2 (en)	1996-10-01	2000-09-14	Smithkline Beecham Corporation	Use of mupirocin for the manufacture of a medicament for the treatment of bacterial infections associated with colonisation of the nasopharynx by pathogenic organisms
UY25225A1 (es) *	1997-10-29	2000-12-29	Smithkline Beecham Plc	Derivados de pleuromutilina utiles como agentes antimicrobianos
ATE450535T1 (de)	2003-09-03	2009-12-15	Glaxo Group Ltd	Neues verfahren zur herstellung von pleuromutilinderivaten
GB0504314D0 (en)	2005-03-02	2005-04-06	Glaxo Group Ltd	Novel polymorph

1996
- 1996-05-07 UY UY25225A patent/UY25225A1/es not_active IP Right Cessation
1998
- 1998-10-27 DK DK08152170.0T patent/DK1930330T3/da active
- 1998-10-27 HU HU0004040A patent/HU229792B1/hu active Protection Beyond IP Right Term
- 1998-10-27 IL IL13581198A patent/IL135811A0/xx active IP Right Grant
- 1998-10-27 PL PL340254A patent/PL191927B1/pl unknown
- 1998-10-27 DE DE69826704T patent/DE69826704T3/de not_active Expired - Lifetime
- 1998-10-27 ES ES98950202T patent/ES2229538T7/es active Active
- 1998-10-27 NZ NZ504203A patent/NZ504203A/xx not_active IP Right Cessation
- 1998-10-27 KR KR10-2000-7004707A patent/KR100538721B1/ko not_active IP Right Cessation
- 1998-10-27 WO PCT/GB1998/003211 patent/WO1999021855A1/fr active IP Right Grant
- 1998-10-27 EP EP08152170A patent/EP1930330B1/fr not_active Expired - Lifetime
- 1998-10-27 EP EP98950202A patent/EP1028961B3/fr not_active Expired - Lifetime
- 1998-10-27 US US09/530,446 patent/US6281226B1/en not_active Ceased
- 1998-10-27 PT PT08152170T patent/PT1930330E/pt unknown
- 1998-10-27 CZ CZ20001551A patent/CZ298543B6/cs not_active IP Right Cessation
- 1998-10-27 AT AT08152170T patent/ATE525373T1/de active
- 1998-10-27 AR ARP980105377A patent/AR015987A1/es active IP Right Grant
- 1998-10-27 AU AU96361/98A patent/AU742167C/en not_active Expired
- 1998-10-27 US US10/631,707 patent/USRE39128E1/en not_active Ceased
- 1998-10-27 US US13/102,156 patent/USRE43390E1/en not_active Expired - Lifetime
- 1998-10-27 AT AT98950202T patent/ATE277925T1/de active
- 1998-10-27 SI SI9830932T patent/SI1930330T1/sl unknown
- 1998-10-27 JP JP2000517965A patent/JP4227729B2/ja not_active Expired - Lifetime
- 1998-10-27 TR TR2000/01203T patent/TR200001203T2/xx unknown
- 1998-10-27 ZA ZA9809767A patent/ZA989767B/xx unknown
- 1998-10-27 EP EP04076485A patent/EP1452534A1/fr not_active Withdrawn
- 1998-10-27 MY MYPI98004896A patent/MY130665A/en unknown
- 1998-10-27 PL PL375435A patent/PL197672B1/pl unknown
- 1998-10-27 DK DK98950202T patent/DK1028961T5/da active
- 1998-10-27 DE DE122007000076C patent/DE122007000076I2/de active Active
- 1998-10-27 ES ES08152170T patent/ES2371205T3/es not_active Expired - Lifetime
- 1998-10-27 BR BRPI9814747-1A patent/BR9814747B1/pt not_active IP Right Cessation
- 1998-10-27 CA CA002307551A patent/CA2307551C/fr not_active Expired - Lifetime
- 1998-10-27 SI SI9830709T patent/SI1028961T1/xx unknown
- 1998-10-27 CN CNB988127318A patent/CN1205211C/zh not_active Expired - Lifetime
- 1998-10-27 PT PT98950202T patent/PT1028961E/pt unknown
- 1998-10-28 DZ DZ980244A patent/DZ2634A1/fr active
- 1998-10-29 EG EG132598A patent/EG24177A/xx active
- 1998-10-29 PE PE1998001018A patent/PE123299A1/es not_active Application Discontinuation
- 1998-10-29 CO CO98063556A patent/CO5021129A1/es unknown
- 1998-11-24 TW TW087119420A patent/TWI232861B/zh not_active IP Right Cessation
2000
- 2000-04-24 IL IL135811A patent/IL135811A/en not_active IP Right Cessation
- 2000-04-27 NO NO20002173A patent/NO327392B1/no not_active IP Right Cessation
2001
- 2001-02-05 HK HK01100820A patent/HK1031376A1/xx not_active IP Right Cessation
2007
- 2007-10-24 LU LU91372C patent/LU91372I2/fr unknown
- 2007-11-06 NL NL300304C patent/NL300304I2/nl unknown
- 2007-11-09 FR FR07C0057C patent/FR07C0057I2/fr active Active
- 2007-11-12 CY CY200700028C patent/CY2007028I1/el unknown
2008
- 2008-08-25 JP JP2008215667A patent/JP2009040789A/ja active Pending
2009
- 2009-04-01 NO NO20091344A patent/NO20091344L/no not_active Application Discontinuation
- 2009-09-25 NO NO2009023C patent/NO2009023I2/no unknown
2011
- 2011-10-31 CY CY20111101037T patent/CY1112062T1/el unknown
2014
- 2014-12-18 HU HUS1400060C patent/HUS1400060I1/hu unknown

Also Published As

Publication number	Publication date
CY2007028I2 (el)	2009-11-04
AU9636198A (en)	1999-05-17
FR07C0057I1 (fr)	2007-12-14
TR200001203T2 (tr)	2000-08-21
EP1028961A1 (fr)	2000-08-23
USRE39128E1 (en)	2006-06-13
CY1112062T1 (el)	2015-11-04
ATE277925T1 (de)	2004-10-15
NL300304I2 (nl)	2008-03-03
DE122007000076I1 (de)	2008-02-14
PT1028961E (pt)	2005-01-31
PL191927B1 (pl)	2006-07-31
CA2307551A1 (fr)	1999-05-06
TWI232861B (en)	2005-05-21
IL135811A (en)	2006-12-31
DK1028961T3 (da)	2005-01-03
PL197672B1 (pl)	2008-04-30
EP1028961B1 (fr)	2004-09-29
NZ504203A (en)	2002-11-26
HUP0004040A1 (hu)	2001-05-28
DE122007000076I2 (de)	2010-03-25
HU229792B1 (en)	2014-07-28
ZA989767B (en)	2000-04-28
WO1999021855A1 (fr)	1999-05-06
CO5021129A1 (es)	2001-03-27
CN1205211C (zh)	2005-06-08
CA2307551C (fr)	2007-01-30
KR100538721B1 (ko)	2005-12-26
AU742167B2 (en)	2001-12-20
USRE43390E1 (en)	2012-05-15
JP2009040789A (ja)	2009-02-26
LU91372I9 (fr)	2019-01-02
CN1283197A (zh)	2001-02-07
BR9814747B1 (pt)	2010-12-14
PL340254A1 (en)	2001-01-29
AR015987A1 (es)	2001-05-30
NO327392B1 (no)	2009-06-22
IL135811A0 (en)	2001-05-20
ATE525373T1 (de)	2011-10-15
PE123299A1 (es)	2000-02-05
ES2229538T7 (es)	2009-06-18
NL300304I1 (nl)	2008-01-02
HUS1400060I1 (hu)	2016-09-28
CZ20001551A3 (cs)	2001-01-17
DK1028961T5 (da)	2009-03-09
CY2007028I1 (el)	2009-11-04
DE69826704T2 (de)	2005-10-06
AU742167C (en)	2003-08-07
SI1028961T1 (en)	2005-02-28
EP1452534A1 (fr)	2004-09-01
EP1930330A1 (fr)	2008-06-11
UY25225A1 (es)	2000-12-29
DK1930330T3 (da)	2011-12-12
NO2009023I1 (no)	2009-10-12
NO20002173D0 (no)	2000-04-27
NO20091344L (no)	2000-06-05
FR07C0057I2 (fr)	2008-05-16
KR20010031654A (ko)	2001-04-16
HUP0004040A3 (en)	2001-08-28
HK1031376A1 (en)	2001-06-15
EP1930330B1 (fr)	2011-09-21
JP4227729B2 (ja)	2009-02-18
NO20002173L (no)	2000-06-05
US6281226B1 (en)	2001-08-28
DE69826704T3 (de)	2009-07-23
DZ2634A1 (fr)	2003-03-08
CZ298543B6 (cs)	2007-10-31
EP1028961B3 (fr)	2008-12-03
DE69826704D1 (de)	2004-11-04
EG24177A (en)	2008-09-28
MY130665A (en)	2007-07-31
JP2001521033A (ja)	2001-11-06
NO2009023I2 (no)	2012-12-03
ES2371205T3 (es)	2011-12-28
BR9814747A (pt)	2001-11-20
PT1930330E (pt)	2011-10-31
SI1930330T1 (sl)	2011-12-30
ES2229538T3 (es)	2005-04-16

Publication	Publication Date	Title
LU91372I2 (fr)	2007-12-24	Retapamulin optionnellement sous forme d'un sel pharmaceutiquement acceptable (altargo)
LU91442I2 (fr)	2008-07-21	"Varénicline, optionnellement sous forme d'un sel pharmaceutiquement acceptable, y compris le sel tartrate"
LU92428I2 (fr)	2014-06-10	Bosutinib, éventuellement sous la forme d'un sel pharmaceutiquement acceptable
LU88809I2 (fr)	1997-01-03	Lamivudine facultativement sous la forme d'un sel pharmaceutiquement acceptable
LU92407I2 (fr)	2014-05-19	Afatinib, éventuellement sous la forme d'un sel pharmaceutiquement acceptable, y compris le sel dimaléate
LU90593I2 (fr)	2000-08-07	Quetiapine facutativement sous forme d'un sel pharmaceutiquement acceptabe
LU91027I2 (fr)	2004-04-28	Dutasteride optionnellement sous forme d'un solvate pharmaceutiquement acceptable
LU91306I2 (fr)	2007-03-19	Mitratapide, optionnellement sous forme d'un sel d'addition acide pharmaceutiquement acceptable (YARVITAN)
LU92699I2 (fr)	2015-06-24	Bazédoxifène, éventuellement sous la forme d'un sel pharmaceutiquement, acceptable tel que le sel d'acétate, et d'estrogènes conjugués
LU88842I2 (fr)	1997-01-27	Nebivolol optionnellement sous forme d'un sel ou d'un hydrate pharmaceutiquement acceptable en particulier hydroclorure de Nebivolol
LU90468I2 (fr)	2000-01-03	Zanamivir facultativement sous la forme d'un sel ou d'un derive pharmaceutiquement acceptable
LU91290I2 (fr)	2007-01-22	Céfovécine, optionnellement sous la forme d'un sel, dont le sel de sodium (CONVENIAr)
LU90426I2 (fr)	1999-10-06	Abacavir facultativement sous la forme d'un sel pharmaceutiquement acceptable ou d'un d-rive y compris le sulfate d'abacavir
IL133672A0 (en)	2001-04-30	Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
LU88746I2 (fr)	1996-10-04	Valaciclovir facultativement sous la forme d'un sel pharmaceutiquement acceptable y compris le sel d'addition de l'acide chlorhydrique
IL127222A0 (en)	2000-06-01	A sustained release pharmaceutical composition containing 1-¬4-¬2-(2-hydroxyethoxy)ethyl¾-1-piperazinyl¾dibenzo¬b,f¾¬1,4¾thiazepine or a pharmaceutically acceptable salt thereof
HK1048617B (zh)	2004-12-03	三維打印的方法
NO2005007I2 (no)	2008-02-11	Pemetrexed og farmasoytisk akseptable salter derav
HUP0100870A3 (en)	2002-11-28	Alpha-aminoamide derivatives useful as analgesic agents
EP1017980A4 (fr)	2002-09-18	Procede d'identification de composes pharmaceutiquement actifs
IL121730A0 (en)	1998-02-22	Process for the preparation of 2'-fluoro-5-methyl-beta-L-arabino-furanosyluridine
IT1295378B1 (it)	1999-05-12	Apparecchiatura per la preparazione di un infuso di caffe'
TW388285U (en)	2000-04-21	Bowler's wrist brace
GB9902966D0 (en)	1999-03-31	Diver's weight-belt
PL341487A1 (en)	2002-01-14	Plater's wedge